Few items that beachgoers use are as distinctly American as their bottles, tubes and cans of sunscreen. But that shouldn’t be a point of pride, according to a coalition of dermatologists, cancer-research groups and sunscreen makers.
Sunscreens sold in the United States are missing some of the latest and most effective ingredients for blocking the type of ultraviolet rays associated with premature aging and serious skin cancer, says the Public Access to Sunscreens Coalition (PASS).
Those ingredients, though widely used in Europe and Asia, have been held up for years at the Food and Drug Administration (FDA). Federal law treats sunscreen as an over-the-counter drug, meaning new formulas must undergo rigorous and costly scrutiny before they hit stores.
The coalition is making a public push for the FDA to get moving. The centerpiece of its efforts is proposed federal legislation, the Sunscreen Innovation Act, which would give FDA a timeline for acting on sunscreen applications.
- Ivar's to raise restaurant workers' wages to $15 right away
- Opening day roster looks pretty clear after Sunday cuts
- WSU study: 'Exploding head syndrome' more common than once thought
- 3 places off the beaten track in Hawaii
- A mom's tweet about Oreos in school stirs up culture wars
Most Read Stories
“Everybody agrees that the process is broken down,” said Wendy Selig, president of the Melanoma Research Alliance, which is part of the PASS coalition.
It’s difficult to pinpoint the reasons for the delays. FDA officials have cited staffing shortages and a lengthy rule-writing process. In 2002, the agency set up what was intended to be a streamlined process for sunscreens, allowing officials to approve ingredients if they have been used for at least five years abroad and have proved effective and safe.
But no ingredients have been approved through that process. Eight applications are pending, some dating to 2003.
FDA spokeswoman Andrea Fischer said Americans have many effective products from which to choose.
She also pointed out FDA notifications to three applicants this year that their scientific evidence is lacking. In other countries, sunscreen is treated as a cosmetic, and the safety data from its use there doesn’t always meet FDA requirements.
“The FDA recognizes the public-health importance of sunscreen use and has prioritized reviewing the safety and effectiveness of additional sunscreen ingredients as quickly as possible given the agency’s resources,” Fischer said.
The FDA has methods for fast-tracking approvals of drugs for serious or life-threatening conditions. Selig noted that in the past four years, there have been at least six new drugs approved for melanoma, the deadliest skin cancer. But there has not been one new sunscreen ingredient approved in that time.
“It’s the same agency,” she said.
Dr. James Spencer, a St. Petersburg dermatologist, said U.S. sunscreens are good at protecting against ultraviolet B rays, which are primarily responsible for sunburns and can cause skin cancers. Protection from UVB is what people shop for when they select sunscreen by its SPF rating.
But he and other dermatologists say U.S. sunscreens have limited ingredients that filter the deeper-penetrating ultraviolet A rays. UVA rays, which can pass through window glass, cause premature aging and are associated with melanoma.
Four of the eight pending applications with the FDA are for ingredients that fight UVA rays, according to the Environmental Working Group, a consumer organization that puts out an annual report on sunscreens.
The best UVA filter in the United States is avobenzone, which is less effective than several products safely used in Europe for years, said Dr. Mary Lien, a dermatologist who practices at several Tampa Bay-area hospitals. Another kind of chemical UVA filters used in the United States, the benzophenones, have caused allergic reactions in some people, she added.
Certain physical blockers such as titanium oxide also work against UVA rays but are impractical for daily use because they deposit a chalky film that few users except lifeguards will tolerate.
In recent years, the FDA has toughened up labeling standards to help consumers pick the best “broad spectrum” sunscreens, those that protect against both UVA and UVB rays. For instance, the agency requires that sunscreens pass a test before they can be labeled broad-spectrum. Critics, including the Environmental Working Group, say that test isn’t stringent enough.
European countries, for instance, require that sunscreens offer UVA protection that is at least a third as potent as the UVB protection measured by SPF. The group estimates that half of the 456 U.S. sunscreens it evaluated this year would be too weak to be sold on the European market.
So do the weaker U.S. sunscreens result in higher skin-cancer rates than other countries? Dr. Steven Wang, director of dermatologic surgery and dermatology at Memorial Sloan-Kettering Cancer Center in New Jersey and a member of the PASS coalition, said that’s difficult to answer. That’s partly because so many people, in every country, aren’t using sunscreen correctly: They don’t reapply it nearly enough, he said, or they assume any use at all gives them license to bake.
“People think it makes them invincible,” he said.